First clinical implementation of GammaTile permanent brain implants after FDA clearance

PurposeGammaTile cesium-131 (131Cs) permanent brain implant has received Food and Drug Administration (FDA) clearance as a promising treatment for certain tumors. Our center was the first institution in United States after FDA to offer clinical use of GammaTile brachytherapy outside trial. The purpose this work is aid medical physicist radiation oncologist implementing collagen carrier tile (CTBT) program their practice.MethodsA total 23 patients have been treated with date at our center. Treatment planning system (TPS) commissioning performed by configuring parameters 131Cs (IsoRay Model CS-1, Rev2) source, doses were validated consensus data from American Association Physicists Medicine TG-43U1S2. Implant procedures, dosimetry, postimplant planning, target delineations established based on experience. Radiation safety aspects evaluated exposure rate measurements implanted patients, well body ring badge measurements.ResultsAn estimated timeframe responsibilities physicist, oncologist, neurosurgeon presented. TPS published dose water 131Cs. Clinical aspects, including estimation number tiles, considerations, are presented.ConclusionThe implementation requires collaboration multiple specialties, physics, oncology, neurosurgery. This manuscript provides roadmap therapy.